TipRanks
Go Ultimate55% OFF

Compare Genscript Biotech (GNNSF) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
GNNSFGenscript Biotech$4.50$10.14B-14.95108.60%Strong BuyUnlock the GNNSF analyst price target with TipRanks PremiumGNNSFUnlock the GNNSF top-analyst price target with TipRanks Premium
HK:2269Wuxi Biologics (Cayman)HKD 44.60HKD 183.11B31.1321.60%Strong BuyUnlock the HK:2269 analyst price target with TipRanks PremiumGNNSF vs HK:2269Unlock the HK:2269 top-analyst price target with TipRanks Premium
HK:3759Pharmaron Beijing Co., Ltd. Class HHKD 27.20HKD 80.45B41.796.14%Strong BuyUnlock the HK:3759 analyst price target with TipRanks PremiumGNNSF vs HK:3759Unlock the HK:3759 top-analyst price target with TipRanks Premium
HK:1521Frontage Holdings Corp.HKD 1.49HKD 3.04B36.5319.20%―Unlock the HK:1521 analyst price target with TipRanks PremiumGNNSF vs HK:1521Unlock the HK:1521 top-analyst price target with TipRanks Premium
HK:1873Viva Biotech HoldingsHKD 1.26HKD 2.60B12.89-47.03%―Unlock the HK:1873 analyst price target with TipRanks PremiumGNNSF vs HK:1873Unlock the HK:1873 top-analyst price target with TipRanks Premium
HK:6821Asymchem Laboratories (Tianjin) Co., Ltd. Class HHKD 107.90HKD 54.78B40.7921.10%Strong BuyUnlock the HK:6821 analyst price target with TipRanks PremiumGNNSF vs HK:6821Unlock the HK:6821 top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%250%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
GNNSFGenscript Biotech4.492.39113.57%
HK:2269Wuxi Biologics (Cayman)44.488.8624.87%
HK:3759Pharmaron Beijing Co., Ltd. Class H26.981.656.50%
HK:1521Frontage Holdings Corp.1.490.3227.35%
HK:1873Viva Biotech Holdings1.25-1.14-47.70%
HK:6821Asymchem Laboratories (Tianjin) Co., Ltd. Class H103.9019.4222.99%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts